Stocks News

LAST PRICE
317.1600
TODAY'S CHANGE (%)
Trending Up2.6000 (0.8266%)

Bid / Lots
316.9000/ 2
Ask / Lots
317.4100/ 4
Open / Previous Close
316.5600 / 314.5600
Day Range
Low 312.7300
High 319.1900
52 Week Range
Low 208.6249
High 325.0000
Volume
117,393
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Today
- DJ United Therapeutics Is Maintained at Buy by UBS, from 33 minutes ago by Dow Jones
  33 minutes ago by Dow Jones
  Companies Mentioned: UTHR
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/UTHR/analyst-ratings
  
  (END) Dow Jones Newswires
  
  July 08, 2024 12:05 ET (16:05 GMT)
- UBS Adjusts Price Target on United Therapeutics to $370 From $300, Maintains Buy Rating, from 3 hours ago by MT Newswires
  3 hours ago by MT Newswires
  Companies Mentioned: UTHR
  09:23 AM EDT, 07/08/2024 (MT Newswires) -- United Therapeutics (UTHR) has an average outperform rating and a price target range of $221 to $400, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic research...
Jun 28, 2024
- United Therapeutics Insider Sold Shares Worth $2,395,035, According to a Recent SEC Filing, from 4:49PM ET on Friday Jun 28, 2024 by MT Newswires
  4:49PM ET on Friday Jun 28, 2024 by MT Newswires
  Companies Mentioned: UTHR
  04:49 PM EDT, 06/28/2024 (MT Newswires) -- Tommy G Thompson, Director, on June 26, 2024, sold 7,500 shares in United Therapeutics (UTHR) for $2,395,035. Following the Form 4 filing with the SEC, Thompson has control over a total of 22,480 shares of ...
- United Therapeutics Insider Sold Shares Worth $2,285,941, According to a Recent SEC Filing, from 4:47PM ET on Friday Jun 28, 2024 by MT Newswires
  4:47PM ET on Friday Jun 28, 2024 by MT Newswires
  Companies Mentioned: UTHR
  04:47 PM EDT, 06/28/2024 (MT Newswires) -- Martine A Rothblatt, Director, Chairperson & CEO, on June 26, 2024, sold 7,200 shares in United Therapeutics (UTHR) for $2,285,941. Following the Form 4 filing with the SEC, Rothblatt has control over a tot...
Jun 27, 2024
- United Therapeutics Corporation Announces Election of Jan Malcolm to its Board of Directors, from 7:00AM ET on Thursday Jun 27, 2024 by Business Wire
  7:00AM ET on Thursday Jun 27, 2024 by Business Wire
  Companies Mentioned: UTHR
  United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced the addition of former Minnesota Commissioner of Health Jan Malcolm to its Board of Directors. Ms. Malcolm was elected by the company's shareholders at its annual meeting held on June 26, 2024.

Today
- Baird Adjusts Medpace Holdings' Price Target to $469 From $456, Keeps Outperform Rating, from 7 minutes ago by MT Newswires
  7 minutes ago by MT Newswires
  Companies Mentioned: MEDP
- DJ Medpace Holdings Is Maintained at Outperform by Baird, from 24 minutes ago by Dow Jones
  24 minutes ago by Dow Jones
  Companies Mentioned: MEDP
Jul 3, 2024
- Neurocrine Biosciences Insider Sold Shares Worth $1,401,864, According to a Recent SEC Filing, from 3:05AM ET on Wednesday Jul 03, 2024 by MT Newswires
  3:05AM ET on Wednesday Jul 03, 2024 by MT Newswires
  Companies Mentioned: NBIX
Jul 1, 2024
- Asian Equities Traded in the US as American Depositary Receipts Open Week on Flat Note, from 10:58AM ET on Monday Jul 01, 2024 by MT Newswires
  10:58AM ET on Monday Jul 01, 2024 by MT Newswires
  Companies Mentioned: GRVY, CCM, RDY, SIFY, WIT, SE, ASLN, HUYA, JG, NIO, WNS, DOYU, BGNE, COE
- Neurocrine Biosciences Says US FDA Accepts NDAs With Priority Review for Adrenal Gland Disease Drug, from 8:22AM ET on Monday Jul 01, 2024 by MT Newswires
  8:22AM ET on Monday Jul 01, 2024 by MT Newswires
  Companies Mentioned: NBIX
- DJ Neurocrine Biosciences Gets FDA Priority Review for Crinecerfont, from 7:54AM ET on Monday Jul 01, 2024 by Dow Jones
  7:54AM ET on Monday Jul 01, 2024 by Dow Jones
  Companies Mentioned: NBIX
- Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH, from 7:30AM ET on Monday Jul 01, 2024 by Dow Jones
  7:30AM ET on Monday Jul 01, 2024 by Dow Jones
  Companies Mentioned: NBIX
Jun 27, 2024
- Wells Fargo Adjusts BioMarin Pharmaceutical Price Target to $115 From $110, Maintains Overweight Rating, from 11:32AM ET on Thursday Jun 27, 2024 by MT Newswires
  11:32AM ET on Thursday Jun 27, 2024 by MT Newswires
  Companies Mentioned: BMRN
- DJ BioMarin Pharmaceutical Is Maintained at Overweight by Wells Fargo, from 11:30AM ET on Thursday Jun 27, 2024 by Dow Jones
  11:30AM ET on Thursday Jun 27, 2024 by Dow Jones
  Companies Mentioned: BMRN
Jun 26, 2024
- Beigene Insider Sold Shares Worth $445,070, According to a Recent SEC Filing, from 5:28PM ET on Wednesday Jun 26, 2024 by MT Newswires
  5:28PM ET on Wednesday Jun 26, 2024 by MT Newswires
  Companies Mentioned: BGNE

United Therapeutics Corp
NASDAQ:UTHRUnited States

Search Criteria

Today

DJ United Therapeutics Is Maintained at Buy by UBS, from 33 minutes ago by Dow Jones

UBS Adjusts Price Target on United Therapeutics to $370 From $300, Maintains Buy Rating, from 3 hours ago by MT Newswires

Jun 28, 2024

United Therapeutics Insider Sold Shares Worth $2,395,035, According to a Recent SEC Filing, from 4:49PM ET on Friday Jun 28, 2024 by MT Newswires

United Therapeutics Insider Sold Shares Worth $2,285,941, According to a Recent SEC Filing, from 4:47PM ET on Friday Jun 28, 2024 by MT Newswires

Jun 27, 2024

United Therapeutics Corporation Announces Election of Jan Malcolm to its Board of Directors, from 7:00AM ET on Thursday Jun 27, 2024 by Business Wire

Peers Headlines

Today

Baird Adjusts Medpace Holdings' Price Target to $469 From $456, Keeps Outperform Rating, from 7 minutes ago by MT Newswires

DJ Medpace Holdings Is Maintained at Outperform by Baird, from 24 minutes ago by Dow Jones

Jul 3, 2024

Neurocrine Biosciences Insider Sold Shares Worth $1,401,864, According to a Recent SEC Filing, from 3:05AM ET on Wednesday Jul 03, 2024 by MT Newswires

Jul 1, 2024

Asian Equities Traded in the US as American Depositary Receipts Open Week on Flat Note, from 10:58AM ET on Monday Jul 01, 2024 by MT Newswires

Neurocrine Biosciences Says US FDA Accepts NDAs With Priority Review for Adrenal Gland Disease Drug, from 8:22AM ET on Monday Jul 01, 2024 by MT Newswires

DJ Neurocrine Biosciences Gets FDA Priority Review for Crinecerfont, from 7:54AM ET on Monday Jul 01, 2024 by Dow Jones

Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH, from 7:30AM ET on Monday Jul 01, 2024 by Dow Jones

Jun 27, 2024

Wells Fargo Adjusts BioMarin Pharmaceutical Price Target to $115 From $110, Maintains Overweight Rating, from 11:32AM ET on Thursday Jun 27, 2024 by MT Newswires

DJ BioMarin Pharmaceutical Is Maintained at Overweight by Wells Fargo, from 11:30AM ET on Thursday Jun 27, 2024 by Dow Jones

Jun 26, 2024

Beigene Insider Sold Shares Worth $445,070, According to a Recent SEC Filing, from 5:28PM ET on Wednesday Jun 26, 2024 by MT Newswires